Fortress Biotech, Inc. (FBIO)Healthcare | Biotechnology | Bay Harbor Islands, United States | NasdaqCM
1.91 USD
+0.01
(0.526%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:51 a.m. EDT
Fortress Biotech presents a classic value trap with deteriorating fundamentals and overwhelming bearish sentiment. While the company boasts a fortress-like balance sheet with cash exceeding market cap and a low book value, the business is bleeding cash with negative operating margins and free cash flow. The price trajectory confirms this distress, having lost over 93% of its value over the last nine years despite a recent annual rebound, indicating the market views the recovery as insufficient to reverse the long-term trend. The options market is screaming caution, with traders aggressively buying puts to hedge against further collapse while calls remain virtually dormant. With no dividend to provide income and a forward P/E that implies continued losses, there is no margin of safety here; the stock is trading at a discount because investors fear the royalty model or clinical pipeline cannot generate the massive returns needed to justify the current valuation. This is a speculative hold at best, likely a cash grab for distressed investors, rather than a viable investment vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.091843 |
| AutoETS | 0.091843 |
| MSTL | 0.092761 |
| AutoTheta | 0.098768 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 18.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.085 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.871 |
| Revenue per Share | 2.252 |
| Market Cap | 63,700,392 |
| Trailing P/E | 0.69 |
| Forward P/E | -1.09 |
| Beta | 1.25 |
| Profit Margins | 163.32% |
| Website | https://www.fortressbiotech.com |
As of Oct. 10, 2026, 6:51 a.m. EDT: Options activity reveals a distinct asymmetry favoring downside protection. Put volume and open interest significantly exceed call volume across nearly all expirations, with notable accumulation of puts at the $2.50 strike and heavy positioning at $5.00 and $7.50 strikes for later dates. Implied volatility is elevated on out-of-the-money puts relative to calls, suggesting speculators are pricing in a high probability of further decline or a binary event failure rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.29259259 |
| Address1 | 1,111 Kane Concourse |
| Address2 | Suite 301 |
| All Time High | 190.5 |
| All Time Low | 1.24 |
| Ask | 1.92 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 285,000 |
| Average Daily Volume3 Month | 449,142 |
| Average Volume | 449,142 |
| Average Volume10Days | 285,000 |
| Beta | 1.248 |
| Bid | 1.92 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 4.927 |
| City | Bay Harbor Islands |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.91 |
| Current Ratio | 3.959 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.95 |
| Day Low | 1.89 |
| Debt To Equity | 25.871 |
| Display Name | Fortress Biotech |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -24,979,000 |
| Ebitda Margins | -0.36484 |
| Enterprise To Ebitda | 1.506 |
| Enterprise To Revenue | -0.549 |
| Enterprise Value | -37,610,604 |
| Eps Forward | -1.76 |
| Eps Trailing Twelve Months | 2.76 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4996 |
| Fifty Day Average Change | -0.58959997 |
| Fifty Day Average Change Percent | -0.23587774 |
| Fifty Two Week Change Percent | -29.259258 |
| Fifty Two Week High | 4.53 |
| Fifty Two Week High Change | -2.6200004 |
| Fifty Two Week High Change Percent | -0.5783665 |
| Fifty Two Week Low | 1.88 |
| Fifty Two Week Low Change | 0.029999971 |
| Fifty Two Week Low Change Percent | 0.015957432 |
| Fifty Two Week Range | 1.88 - 4.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,321,540,200,000 |
| Float Shares | 21,443,021 |
| Forward Eps | -1.76 |
| Forward P E | -1.0852273 |
| Free Cashflow | -17,136,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 78 |
| Fullday Change | 0.01999998 |
| Fullday Change Percent | 1.0526305 |
| Fullday Price | 1.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.63278 |
| Gross Profits | 43,324,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23903999 |
| Held Percent Institutions | 0.31248 |
| Implied Shares Outstanding | 33,350,993 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,696,896,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. |
| Long Name | Fortress Biotech, Inc. |
| Market | us_market |
| Market Cap | 63,700,392 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_61731337 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 103,367,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,041,323 |
| Number Of Analyst Opinions | 1 |
| Open | 1.91 |
| Operating Cashflow | 125,920,000 |
| Operating Margins | -0.53457 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 781 652 4500 |
| Previous Close | 1.9 |
| Price Hint | 4 |
| Price To Book | 0.38765982 |
| Price To Sales Trailing12 Months | 0.93039453 |
| Profit Margins | 1.63319 |
| Quick Ratio | 3.762 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.526315 |
| Regular Market Day High | 1.95 |
| Regular Market Day Low | 1.89 |
| Regular Market Day Range | 1.89 - 1.95 |
| Regular Market Open | 1.91 |
| Regular Market Previous Close | 1.9 |
| Regular Market Price | 1.91 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 219,436 |
| Return On Assets | -0.07757 |
| Return On Equity | 1.15985 |
| Revenue Growth | 0.14 |
| Revenue Per Share | 2.252 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 33,350,993 |
| Shares Percent Shares Out | 0.1469 |
| Shares Short | 4,898,052 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,443,900 |
| Short Name | Fortress Biotech, Inc. |
| Short Percent Of Float | 0.19 |
| Short Ratio | 17.93 |
| Source Interval | 15 |
| State | FL |
| Symbol | FBIO |
| Target High Price | 5.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 196,576,000 |
| Total Cash Per Share | 5.894 |
| Total Debt | 53,316,000 |
| Total Revenue | 68,466,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.76 |
| Trailing P E | 0.692029 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.90245 |
| Two Hundred Day Average Change | -0.9924501 |
| Two Hundred Day Average Change Percent | -0.3419353 |
| Type Disp | Equity |
| Volume | 219,436 |
| Website | https://www.fortressbiotech.com |
| Zip | 33,154 |